| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c2b9dc89cc4ba060cc73bbf0c90bbb78 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-64 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-64 |
| filingDate |
2001-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df764596607567595fd2fc205a06514e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b6face648ea1753ab76b90b91c7c82e |
| publicationDate |
2002-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2002016287-A1 |
| titleOfInvention |
Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
| abstract |
A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser, an insulin secretagogue and a biguanide antihyperglycaemic agent, to a mammal in need thereof; and composition for use in such method. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009081314-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8911781-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007004780-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013004436-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005059706-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003109553-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008058388-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004092555-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9248110-B2 |
| priorityDate |
1997-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |